| 1 | English French Notes Complete/Exclude
|
|---|
| 2 | FIRST COURSE OF TREATMENT - RADIATION
|
|---|
| 3 | 38. REGIONAL DOSE (cGy)...........:
|
|---|
| 4 | 39. BOOST DOSE (cGy)..............:
|
|---|
| 5 | 40. INTRA-OPERATIVE RADIATION
|
|---|
| 6 | 41. CONCURRENT CHEMOTHERAPY.......:
|
|---|
| 7 | FIRST COURSE OF TREATMENT - CHEMOTHERAPY
|
|---|
| 8 | 42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
|
|---|
| 9 | 43. INTRAPERITONEAL CHEMOTHERAPY..:
|
|---|
| 10 | 44. CHEMOTHERAPEUTIC TOXICITY.....:
|
|---|
| 11 | 45. CHEMOTHERAPY/SURGERY SEQUENCE.:
|
|---|
| 12 | FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
|
|---|
| 13 | 46. ADMINISTRATION OF INTERFERON..:
|
|---|
| 14 | TREATMENT COMPLICATIONS
|
|---|
| 15 | CASE REGISTRATION
|
|---|
| 16 | 48. INITIALS OF CASE ABSTRACTOR...:
|
|---|
| 17 | 49. DATE CASE WAS ABSTRACTED......:
|
|---|
| 18 | The Accession Year is not 2000.
|
|---|
| 19 | 2000 Patient Care Evaluation Study of Hepatocellular Cancers
|
|---|
| 20 | 1. FACILITY ID NUMBER (FIN)
|
|---|
| 21 | 5. PLACE OF BIRTH
|
|---|
| 22 | 6. DATE OF BIRTH
|
|---|
| 23 | 8. SPANISH ORIGIN
|
|---|
| 24 | 10. PRIMARY PAYER AT DIAGNOSIS
|
|---|
| 25 | 1. FACILITY ID NUMBER (FIN)
|
|---|
| 26 | 5. PLACE OF BIRTH
|
|---|
| 27 | 6. DATE OF BIRTH
|
|---|
| 28 | 8. SPANISH ORIGIN
|
|---|
| 29 | 1. FACILITY ID NUMBER (FIN)......:
|
|---|
| 30 | 2. ACCESSION NUMBER..............:
|
|---|
| 31 | 3. SEQUENCE NUMBER...............:
|
|---|
| 32 | 9 4. POSTAL CODE AT DIAGNOSIS......
|
|---|
| 33 | 7 5. PLACE OF BIRTH................
|
|---|
| 34 | 6. DATE OF BIRTH.................:
|
|---|
| 35 | 9 8. SPANISH ORIGIN................
|
|---|
| 36 | 18 10. PRIMARY PAYER AT DIAGNOSIS....
|
|---|
| 37 | 11. CLASS OF CASE
|
|---|
| 38 | 13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS
|
|---|
| 39 | 14. ALCOHOL CONSUMPTION
|
|---|
| 40 | 15. TUMOR MARKERS
|
|---|
| 41 | 16. TESTS RELATED TO LIVER FUNCTION
|
|---|
| 42 | 17. RADIOLOGICAL EVALUATION
|
|---|
| 43 | 18. DEFINITIVE DIAGNOSIS
|
|---|
| 44 | 19. DATE OF INITIAL DIAGNOSIS
|
|---|
| 45 | 22. DIAGNOSTIC CONFIRMATION
|
|---|
| 46 | TUMOR IDENTIFICATION
|
|---|
| 47 | 11. CLASS OF CASE.................:
|
|---|
| 48 | 1000 ORAL CONTRACEPTIVES..........
|
|---|
| 49 | 1001 ESTROGEN REPLACEMENT.........
|
|---|
| 50 | 13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS:
|
|---|
| 51 | 1012 14. ALCOHOL CONSUMPTION...........
|
|---|
| 52 | 15. TUMOR MARKERS:
|
|---|
| 53 | 16. TESTS RELATED TO LIVER FUNCTION:
|
|---|
| 54 | 17. RADIOLOGICAL EVALUATION:
|
|---|
| 55 | CT ARTERIAL PORTOGRAPHY:
|
|---|
| 56 | 1022 VASCULAR INVASION............
|
|---|
| 57 | 1023 BILOBAR DISEASE..............
|
|---|
| 58 | 1024 LYMPH NODES..................
|
|---|
| 59 | 1025 SIZE OF DOMINANT TUMOR (mm)..
|
|---|
| 60 | 1026 NUMBER OF TUMORS.............
|
|---|
| 61 | SPIRAL CT:
|
|---|
| 62 | 1029 VASCULAR INVASION............
|
|---|
| 63 | 1030 BILOBAR DISEASE..............
|
|---|
| 64 | 1031 LYMPH NODES..................
|
|---|
| 65 | 1032 SIZE OF DOMINANT TUMOR (mm)..
|
|---|
| 66 | 1033 NUMBER OF TUMORS.............
|
|---|
| 67 | INCREMENTAL CT:
|
|---|
| 68 | 1036 VASCULAR INVASION............
|
|---|
| 69 | 1037 BILOBAR DISEASE..............
|
|---|
| 70 | 1038 LYMPH NODES..................
|
|---|
| 71 | 1039 SIZE OF DOMINANT TUMOR (mm)..
|
|---|
| 72 | 1040 NUMBER OF TUMORS.............
|
|---|
| 73 | 1043 VASCULAR INVASION............
|
|---|
| 74 | 1044 BILOBAR DISEASE..............
|
|---|
| 75 | 1045 LYMPH NODES..................
|
|---|
| 76 | 1046 SIZE OF DOMINANT TUMOR (mm)..
|
|---|
| 77 | 1047 NUMBER OF TUMORS.............
|
|---|
| 78 | 1050 VASCULAR INVASION............
|
|---|
| 79 | 1051 BILOBAR DISEASE..............
|
|---|
| 80 | 1052 LYMPH NODES..................
|
|---|
| 81 | 1053 SIZE OF DOMINANT TUMOR (mm)..
|
|---|
| 82 | 1054 NUMBER OF TUMORS.............
|
|---|
| 83 | 1055 18. DEFINITIVE DIAGNOSIS..........
|
|---|
| 84 | 19. DATE OF INITIAL DIAGNOSIS.....:
|
|---|
| 85 | 22. DIAGNOSTIC CONFIRMATON........:
|
|---|
| 86 | VASCULAR INVASION............: NA
|
|---|
| 87 | BILOBAR DISEASE..............: NA
|
|---|
| 88 | LYMPH NODES..................: NA
|
|---|
| 89 | SIZE OF DOMINANT TUMOR (mm)..: Not performed
|
|---|
| 90 | NUMBER OF TUMORS.............: Not performed
|
|---|
| 91 | VASCULAR INVASION............: Unknown
|
|---|
| 92 | BILOBAR DISEASE..............: Unknown
|
|---|
| 93 | LYMPH NODES..................: Unknown
|
|---|
| 94 | 23. SIZE OF TUMOR
|
|---|
| 95 | 24. REGIONAL NODES EXAMINED
|
|---|
| 96 | 25. REGIONAL NODES POSITIVE
|
|---|
| 97 | 26. AJCC CLINICAL STAGE (cTNM)
|
|---|
| 98 | 27. AJCC PATHOLOGIC STAGE (pTNM)
|
|---|
| 99 | 28. STAGED BY
|
|---|
| 100 | STAGE OF DISEASE AT DIAGNOSIS
|
|---|
| 101 | 29 23. SIZE OF TUMOR ................
|
|---|
| 102 | 33 24. REGIONAL NODES EXAMINED.......
|
|---|
| 103 | 32 25. REGIONAL NODES POSITIVE.......
|
|---|
| 104 | 26. AJCC CLINICAL STAGE (cTNM):
|
|---|
| 105 | 37.1 AJCC CLINICAL T..............
|
|---|
| 106 | 37.2 AJCC CLINICAL N..............
|
|---|
| 107 | 37.3 AJCC CLINICAL M..............
|
|---|
| 108 | 27. AJCC PATHOLOGIC STAGE (pTNM):
|
|---|
| 109 | 85 AJCC PATHOLOGIC T............
|
|---|
| 110 | 86 AJCC PATHOLOGIC N............
|
|---|
| 111 | 87 AJCC PATHOLOGIC M............
|
|---|
| 112 | 28. STAGED BY:
|
|---|
| 113 | 19 CLINICALLY STAGED BY.........
|
|---|
| 114 | 89 PATHOLOGICALLY STAGED BY.....
|
|---|
| 115 | 29. DATE OF FIRST COURSE OF TREATMENT
|
|---|
| 116 | 30. DATE OF INPATIENT ADMISSION
|
|---|
| 117 | 31. DATE OF INPATIENT DISCHARGE
|
|---|
| 118 | 32. DATE OF NON CANCER-DIRECTED SURGERY
|
|---|
| 119 | 33. NON CANCER-DIRECTED SURGERY
|
|---|
| 120 | 34. DATE OF CANCER-DIRECTED SURGERY
|
|---|
| 121 | 35. SURGICAL APPROACH
|
|---|
| 122 | 36. SURGERY OF PRIMARY SITE
|
|---|
| 123 | 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR
|
|---|
| 124 | 39. SURGICAL MARGINS
|
|---|
| 125 | 40. DISTANCE OF TUMOR TO CLOSEST MARGIN
|
|---|
| 126 | 41. SURGERY OF REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S)
|
|---|
| 127 | 42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR
|
|---|
| 128 | 43. RECONSTRUCTION/RESTORATION-FIRST COURSE
|
|---|
| 129 | 44. DATE RADIATION STARTED
|
|---|
| 130 | 45. RADIATION THERAPY
|
|---|
| 131 | 46. DATE CHEMOTHERAPY STARTED
|
|---|
| 132 | 48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED
|
|---|
| 133 | 49. ROUTE CHEMOTHERAPY ADMINISTERED
|
|---|
| 134 | 50. CHEMOTHERAPY/SURGERY SEQUENCE
|
|---|
| 135 | OTHER THERAPY
|
|---|
| 136 | 51. DATE OTHER TREATMENT STARTED
|
|---|
| 137 | 52. OTHER TREATMENT
|
|---|
| 138 | 53. ARTERIAL EMBOLIZATION
|
|---|
| 139 | 54. DEATH WITHIN30 DAYS OF START OF INTIIAL COURSE OF THERAPY
|
|---|
| 140 | FIRST COURSE OF TREATMENT
|
|---|
| 141 | 29. DATE OF FIRST COURSE OF
|
|---|
| 142 | 1 30. DATE OF INPATIENT ADMISSION...
|
|---|
| 143 | 1.1 31. DATE OF INPATIENT DISCHARGE...
|
|---|
| 144 | 32. DATE OF NON CANCER-DIRECTED
|
|---|
| 145 | 33. NON CANCER-DIRECTED SURGERY...:
|
|---|
| 146 | 34. DATE OF CANCER-DIRECTED
|
|---|
| 147 | 35. SURGICAL APPROACH.............:
|
|---|
| 148 | 36. SURGERY OF PRIMARY SITE.......:
|
|---|
| 149 | 37. RADIO-FREQUENCY DESTRUCTION OF
|
|---|
| 150 | 1056 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR........................
|
|---|
| 151 | 38. ABLATION & RESECTION..........: Ablation & resection not administered
|
|---|
| 152 | 39. SURGICAL MARGINS..............:
|
|---|
| 153 | 40. DISTANCE OF TUMOR TO CLOSEST
|
|---|
| 154 | 1058 40. DISTANCE OF TUMOR TO CLOSEST MARGIN.......................
|
|---|
| 155 | 41. SURGERY OF OTHER REGIONAL
|
|---|
| 156 | SITE(S), DISTANT SITE(S),
|
|---|
| 157 | OR DISTANT LYMPH NODE(S).....:
|
|---|
| 158 | 42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR:
|
|---|
| 159 | FIRST COURSE.................:
|
|---|
| 160 | 44. DATE RADIATION STARTED........:
|
|---|
| 161 | 45. RADIATION THERAPY.............:
|
|---|
| 162 | 46. DATE CHEMOTHERAPY STARTED.....:
|
|---|
| 163 | 48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
|
|---|
| 164 | CISPLATIN....................: Unknown if recommended or administered
|
|---|
| 165 | FUDR.........................: Unknown if recommended or administered
|
|---|
| 166 | 5-FU.........................: Unknown if recommended or administered
|
|---|
| 167 | FU & LEUCOVORIN..............: Unknown if recommended or administered
|
|---|
| 168 | IRINOTECAN (CPT-11)..........: Unknown if recommended or administered
|
|---|
| 169 | MITOMYCIN C..................: Unknown if recommended or administered
|
|---|
| 170 | OXALIPLATIN..................: Unknown if recommended or administered
|
|---|
| 171 | GEMCITABINE..................: Unknown if recommended or administered
|
|---|
| 172 | 49. ROUTE CHEMOTHERAPY ADMIN......: NA
|
|---|
| 173 | 1069 49. ROUTE CHEMOTHERAPY ADMIN
|
|---|
| 174 | 50. CHEMOTHERAPY/SURGERY SEQUENCE.: No chemotherapy and/or no surgery
|
|---|
| 175 | 50. CHEMOTHERAPY/SURGERY SEQUENCE.: Chemotherapy before surgery
|
|---|
| 176 | 1070 50. CHEMOTHERAPY/SURGERY SEQUENCE.
|
|---|
| 177 | OTHER THERAPY
|
|---|
| 178 | 51. DATE OTHER TREATMENT STARTED..:
|
|---|
| 179 | 52. OTHER TREATMENT...............:
|
|---|
| 180 | 1071 53. ARTERIAL EMBOLIZATION.........
|
|---|
| 181 | 1072 54. DEATH WITHIN 30 DAYS OF START OF INITIAL COURSE OF THERAPY.
|
|---|
| 182 | 55. DATE OF FIRST RECURRENCE
|
|---|
| 183 | 56. TYPE OF FIRST RECURRENCE
|
|---|
| 184 | 55. TYPE OF FIRST RECURRENCE
|
|---|
| 185 | 56. DATE OF FIRST RECURRENCE
|
|---|
| 186 | 70 55. DATE OF FIRST RECURRENCE
|
|---|
| 187 | 71 56. TYPE OF FIRST RECURRENCE
|
|---|
| 188 | 57. DATE OF LAST CONTACT OR DEATH
|
|---|
| 189 | 58. VITAL STATUS
|
|---|
| 190 | 59. CANCER STATUS
|
|---|
| 191 | 57. DATE OF LAST CONTACT OR DEATH..:
|
|---|
| 192 | 15 58. VITAL STATUS...................
|
|---|
| 193 | 59. CANCER STATUS..................:
|
|---|
| 194 | 1. FACILITY ID NUMBER (FIN)....:
|
|---|
| 195 | 2. ACCESSION NUMBER............:
|
|---|
| 196 | 3. SEQUENCE NUMBER.............:
|
|---|
| 197 | 4. POSTAL CODE AT DIAGNOIS.....:
|
|---|
| 198 | 5. PLACE OF BIRTH..............:
|
|---|
| 199 | 6. DATE OF BIRTH...............:
|
|---|
| 200 | 8. SPANISH ORIGIN..............:
|
|---|
| 201 | 10. PRIMARY PAYER AT DIAGNOSIS..:
|
|---|
| 202 | TUMOR IDENTIFICATION
|
|---|
| 203 | 11. CLASS OF CASE...............:
|
|---|
| 204 | ORAL CONTRACEPTIVES........:
|
|---|
| 205 | ESTROGEN REPLACEMENT.......:
|
|---|
| 206 | 14. ALCOHOL CONSUMPTION.........:
|
|---|
| 207 | 15. TUMOR MARKERS:
|
|---|
| 208 | 16. TESTS RELATED TO LIVER FUNCTION:
|
|---|
| 209 | CT ARTERIAL PORTOGRAPHY:
|
|---|
| 210 | VASCULAR INVASTION.........:
|
|---|
| 211 | BILOBAR DISEASE............:
|
|---|
| 212 | LYMPH NODES................:
|
|---|
| 213 | SIZE OF DOMINANT TUMOR (MM):
|
|---|
| 214 | NUMBER OF TUMORS...........:
|
|---|
| 215 | SPIRAL CT:
|
|---|
| 216 | INCREMENTAL CT:
|
|---|
| 217 | 18. DEFINITIVE DIAGNOSIS........:
|
|---|
| 218 | 19. DATE OF INITIAL DIAGNOSIS...:
|
|---|
| 219 | 22. DIAGNOSTIC CONFIRMATION.....:
|
|---|
| 220 | Print Hepatocellular Cancer PCE
|
|---|
| 221 | STAGE OF DISEASE AT DIAGNOSIS
|
|---|
| 222 | 23. SIZE OF TUMOR...............:
|
|---|
| 223 | 24. REGIONAL NODES EXAMINED.....:
|
|---|
| 224 | 25. REGIONAL NODES POSITIVE.....:
|
|---|
| 225 | 26. AJCC CLINICAL STAGE (cTNM):
|
|---|
| 226 | AJCC CLINICAL T............:
|
|---|
| 227 | AJCC CLINICAL N............:
|
|---|
| 228 | AJCC CLINICAL M............:
|
|---|
| 229 | AJCC CLINICAL STAGE GROUP..:
|
|---|
| 230 | 27. AJCC PATHOLOGIC STAGE (pTNM):
|
|---|
| 231 | AJCC PATHOLOGIC T..........:
|
|---|
| 232 | AJCC PATHOLOGIC N..........:
|
|---|
| 233 | AJCC PATHOLOGIC M..........:
|
|---|
| 234 | AJCC PATHOLOGIC STAGE GROUP:
|
|---|
| 235 | 28. STAGED BY:
|
|---|
| 236 | CLINICALLY STAGED BY.......:
|
|---|
| 237 | PATHOLOGICALLY STAGED BY...:
|
|---|
| 238 | FIRST COURSE OF TREATMENT
|
|---|
| 239 | 29. DATE OF FIRST COURSE OF
|
|---|
| 240 | 30. DATE OF INPATIENT ADMISSION.:
|
|---|
| 241 | 31. DATE OF INPATIENT DISCHARGE.:
|
|---|
| 242 | 32. DATE OF NON CANCER-DIRECTED
|
|---|
| 243 | 33. NON CANCER-DIRECTED SURGERY.:
|
|---|
| 244 | 34. DATE OF CANCER-DIRECTED
|
|---|
| 245 | 35. SURGICAL APPROACH...........:
|
|---|
| 246 | 36. SURGERY OF PRIMARY SITE.....:
|
|---|
| 247 | 37. RADIO-FREQUENCY DESTRUCTION
|
|---|
| 248 | OF TUMOR...................:
|
|---|
| 249 | 39. SURGICAL MARGINS............:
|
|---|
| 250 | 40. DISTANCE OF TUMOR TO CLOSEST
|
|---|
| 251 | 41. SURGERY OF OTHER REGIONAL
|
|---|
| 252 | OR DISTANT LYMPH NODE(S)...:
|
|---|
| 253 | FIRST COURSE...............:
|
|---|
| 254 | 44. DATE RADIATION STARTED......:
|
|---|
| 255 | 45. RADIATION THERAPY...........:
|
|---|
| 256 | 46. DATE CHEMOTHERAPY STARTED...:
|
|---|
| 257 | 49. ROUTE CHEMOTHERAPY ADMIN....:
|
|---|
| 258 | 50. CHEMOTHERAPY/SURGERY SEQ....:
|
|---|
| 259 | 51. DATE OTHER TREATMENT STARTED:
|
|---|
| 260 | 52. OTHER TREATMENT.............:
|
|---|
| 261 | 53. ARTERIAL EMBOLIZATION.......:
|
|---|
| 262 | 54. DEATH WITHIN 30 DAYS OF
|
|---|
| 263 | START OF INITIAL COURSE OF
|
|---|
| 264 | 55. DATE OF FIRST RECURRENCE....:
|
|---|
| 265 | 56. TYPE OF FIRST RECURRENCE....:
|
|---|
| 266 | 57. DATE OF LAST CONTACT/DEATH..:
|
|---|
| 267 | 58. VITAL STATUS................:
|
|---|
| 268 | 59. CANCER STATUS...............:
|
|---|
| 269 | The Class of Case code is not 0, 1, 2 or 5.
|
|---|
| 270 | The Behavior Code is not 0, 1 or 3.
|
|---|
| 271 | 2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
|
|---|
| 272 | 2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
|
|---|
| 273 | 10. PRIOR EXPOSURE TO RADIATION
|
|---|
| 274 | 11. PRIMARY PAYER AT DIAGNOSIS
|
|---|
| 275 | 12. PRIOR MEDICAL CONDITIONS
|
|---|
| 276 | 14. GENETIC PREDISPOSITION
|
|---|
| 277 | 15. USUAL OCCUPATION
|
|---|
| 278 | 16. USUAL INDUSTRY
|
|---|
| 279 | 5. DATE OF BIRTH.................:
|
|---|
| 280 | 9 7. SPANISH ORIGIN................
|
|---|
| 281 | 403 10. PRIOR EXPOSURE TO RADIATION...
|
|---|
| 282 | 18 11. PRIMARY PAYER AT DIAGNOSIS....
|
|---|
| 283 | 12. PRIOR MEDICAL CONDITIONS:
|
|---|
| 284 | 1202 MULTIPLE SCLEROSIS (MS)......
|
|---|
| 285 | 354 MYOCARDIAL INFARCTION (MI)...
|
|---|
| 286 | 1204 CEREBROVASCULAR DISEASE......
|
|---|
| 287 | 1208 MALIGNANT MELANOMA...........
|
|---|
| 288 | 1209 OTHER SKIN CANCER............
|
|---|
| 289 | 1211 COLON OR OTHER GI CANCERS....
|
|---|
| 290 | 14. GENETIC PREDISPOSITION:
|
|---|
| 291 | 1214 VON HIPPEL-LINDAU DISEASE....
|
|---|
| 292 | 1215 TUBEROUS SCLEROSIS...........
|
|---|
| 293 | 1216 TURCOT SYNDROME..............
|
|---|
| 294 | 1217 LI-FRAUMENI SYNDROME.........
|
|---|
| 295 | 1218 KOWDEN DISEASE...............
|
|---|
| 296 | 1219 NEVOID BASAL CELL CARCINOMA..
|
|---|
| 297 | 15. USUAL OCCUPATION..............:
|
|---|
| 298 | 16. USUAL INDUSTRY................:
|
|---|
| 299 | 17. CLASS OF CASE
|
|---|
| 300 | 19. NEUROLOGICAL FINDINGS
|
|---|
| 301 | 20. PRE-THERAPY DIAGNOSTIC STUDIES
|
|---|
| 302 | 21. TUMOR LOCATION/INVOLVEMENT
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
